BTIG Reiterates Biohaven (BHVN) Buy Recommendation

BTIG reiterated Buy on Biohaven (BHVN) on Nov. 18, 2025, and Fintel reports the consensus one‑year price target at $25.95 — a 213.74% upside from the $8.27 close (range $9.09–$56.70). The company’s projected annual revenue is $53 million with projected non‑GAAP EPS of -5.07, underscoring continued unprofitability despite the bullish price targets. Institutional positioning is mixed: 528 funds hold BHVN (up 10 holders quarter‑over‑quarter) and average portfolio weight rose 19.4% to 0.13%, but total institutional shares fell 4.28% to 97,857K; major holders (Janus, Stifel, Suvretta, Vanguard, Bellevue) show varied changes in share counts and large reductions in portfolio allocation. With a put/call ratio of 0.46 signaling options market bullishness, the research suggests sizable upside expectations that contrast with weak fundamentals and uneven institutional conviction, making BHVN a high‑risk, high‑reward exposure for funds.

Analysis

BTIG reiterated coverage of Biohaven (BHVN) with a Buy on November 18, 2025, and the one-year consensus price target is $25.95 as of November 17, 2025 — a 213.74% implied upside from the $8.27 close with a range of $9.09–$56.70, underscoring notable analyst optimism despite current share price levels. The company’s projected annual revenue of $53 million and projected non-GAAP EPS of -5.07 indicate continued unprofitability and limited near-term earnings support for that bullish valuation.

Institutional positioning is mixed: 528 funds hold BHVN (up 10 holders, +1.93% quarter-over-quarter) and average portfolio weight rose 19.38% to 0.13%, while total institutional shares fell 4.28% to 97,857K, reflecting both fresh interest and active de-risking. Large holders show divergent behavior — Janus increased share count to 6,772K but cut allocation by 48.81%, Stifel holds ~6,611K but reduced allocation by 76.68%, and Vanguard increased shares yet reduced allocation by 40.34% — signaling rebalancing rather than conviction-driven accumulation.

Options sentiment is bullish with a put/call ratio of 0.46, which, together with wide analyst targets, suggests the market is pricing a high-reward, high-volatility scenario. The gap between elevated price targets and weak fundamentals implies this is a speculative trade dependent on positive operational or clinical catalysts; investors should expect significant price volatility and monitor institutional flows and fundamental updates for confirmation.

Key Decisions for Investors

• Consider only a small, risk-defined position or time-limited options exposure to capture upside given the 213.74% implied analyst target versus negative non-GAAP EPS
• Avoid increasing core long-term allocations until Biohaven demonstrates revenue growth above the reported $53MM projection or tangible improvement in EPS trajectory
• If currently long, consider selling into strength or using protective hedges given mixed institutional de-risking (total shares down 4.28%) and sizable allocation cuts by major holders
• Monitor near-term catalysts, quarterly top-line and EPS revisions, and options/ownership flows for confirmation before materially adding to exposure